Palatin halves workforce and puts all behind bremelanotide for sexual dysfunction
This article was originally published in Scrip
Palatin Technologies is halving its workforce to 20 people and stopping all preclinical R&D activities in a bid to conserve cash. The company will use its funds to finance the clinical development of its lead candidate bremelanotide, for male and female sexual dysfunction, and PL-3994 for acute severe asthma.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.